BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Vassiliadis T, Patsiaoura K, Tziomalos K, Gkiourtzis T, Giouleme O, Grammatikos N, Rizopoulou D, Nikolaidis N, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006; 12(15): 2417-2422 [PMID: 16688836 DOI: 10.3748/wjg.v12.i15.2417]
URL: https://www.wjgnet.com/1007-9327/full/v12/i15/2417.htm
Number Citing Articles
1
Themistoklis G Vassiliadis, Olga Giouleme, Georgios Koumerkeridis, Haralabos Koumaras, Konstantinos Tziomalos, Kalliopi Patsiaoura, Nikolaos Grammatikos, Alexandros Mpoumponaris, Dimitrios Gkisakis, Konstantinos Theodoropoulos, Athanasia Panderi, Panagiotis Katsinelos, Nikolaos Eugenidis. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine‐resistant HBeAg‐ chronic hepatitis B patients: A 4‐year studyJournal of Gastroenterology and Hepatology 2010; 25(1): 54 doi: 10.1111/j.1440-1746.2009.05952.x
2
Dong Jin Suh, Han Chu Lee, Kwan Soo Byun, Mong Cho, Young Oh Kweon, Won Young Tak, Chae Yoon Chon, Kwang Cheol Koh, Young Sok Lee. Efficacy and Safety of Pegylated Interferon-α2A in Patients with Lamivudine-Resistant Hbeag-Positive Chronic Hepatitis BAntiviral Therapy 2013; 18(6): 765 doi: 10.3851/IMP2664
3
Xiao-Ling Wang, Song-Gang Xie, Ling Zhang, Wei-Xia Yang, Xing Wang, Hong-Zhi Jin. Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis BWorld Journal of Gastroenterology 2008; 14(1): 120-124 doi: 10.3748/wjg.14.120
4
Oliver A. Perez, Brian Berman. Clinical and Basic Immunodermatology2008; : 3 doi: 10.1007/978-1-84800-165-7_1
5
Gulden Eser Karlidag, Turgut Karlidag, Kutbettin Demirdag, Erol Keles. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis BAuris Nasus Larynx 2011; 38(3): 312 doi: 10.1016/j.anl.2010.10.007
6
Patrick Marcellin, Joseph Sung, Teerha Piratvisuth. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferonLiver International 2010; 30(5): 657 doi: 10.1111/j.1478-3231.2010.02207.x
7
Zhi-Jun Yang, Mei-Zeng Tu, Jian Liu, Xiao-Ling Wang, Hong-Zhi Jin. Comparison of amplicon-sequencing, pyrosequencing and real-time PCR for detection of YMDD mutants in patients with chronic hepatitis BWorld Journal of Gastroenterology 2006; 12(44): 7192-7196 doi: 10.3748/wjg.v12.i44.7192
8
Solange Heller, Pedro Valencia-Mayoral. Treatment of Viral Hepatitis in ChildrenArchives of Medical Research 2007; 38(6): 702 doi: 10.1016/j.arcmed.2006.09.005
9
Won Haing Hur, Hyun Young Woo, Soung Won Jeong, Chan Ran You, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon. A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infectionThe Korean Journal of Hepatology 2008; 14(4): 513 doi: 10.3350/kjhep.2008.14.4.513
10
J. Sun, J.-L. Hou, Q. Xie, X.-H. Li, J.-M. Zhang, Y.-M. Wang, H. Wang, J.-Y. Lai, S.-J. Chen, J.-D. Jia, J.-F. Sheng, H. L. Y. Chan, J.-F. Wang, M. K. K. Li, M. Jiang, M. Popescu, J. J. Y. Sung. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistanceAlimentary Pharmacology & Therapeutics 2011; 34(4): 424 doi: 10.1111/j.1365-2036.2011.04750.x